Spero Therapeutics (SPRO) Assets (2016 - 2026)

Spero Therapeutics (SPRO) has reported Assets for 11 consecutive years, with $52.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 15.06% year-over-year to $52.8 million; the trailing twelve-month figure through Jun 2026 stood at $52.8 million (down 15.06% YoY), and the FY2025 full-year result was $68.9 million, down 37.65% from the prior year.
• Assets retreated to $52.8 million in Q2 2026 per SPRO's latest filing, from $59.0 million in the prior quarter.
• Across five years, Assets topped out at $182.4 million in Q4 2023 and bottomed at $52.8 million in Q2 2026.
• Historically, Assets has averaged $102.1 million across 5 years, with a median of $103.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Assets jumped 66.11% in 2023, then tumbled 59.92% in 2025.
• Over 5 years, Assets stood at $124.8 million in 2022, then jumped by 46.14% to $182.4 million in 2023, then sank by 39.39% to $110.5 million in 2024, then tumbled by 37.65% to $68.9 million in 2025, then retreated by 23.44% to $52.8 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $52.8 million, $59.0 million, and $68.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.